Merck Reports Phase 3 MELODY Trial Results for Clesrovimab in RSV Prevention in Infants

Merck today announced results from the Phase 3 MELODY trial evaluating clesrovimab, a monoclonal antibody, for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infections in infants. The trial demonstrated a significant reduction in medically attended RSV-associated lower respiratory tract infections compared to placebo.